Paracetamol IV Market, By Type, By Application, By End User, By Geography

Description

Global paracetamol IV market is estimated to be valued at USD 838.1 Mn in 2024 and is expected to reach USD 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 838.1 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	3.30%	2031 Value Projection:	US$ 1,054.1 Mn

Figure. Paracetamol IV Market Share (%), By Region 2024

Paracetamol, also known as acetaminophen, is among the most commonly used over-the-counter pain reliever and fever reducer. It is primarily used for treating headaches, muscle aches, backaches, toothaches, colds, and fevers. The intravenous route enables faster absorption of paracetamol into the bloodstream compared to the oral route. This makes the intravenous formulation a suitable option for patients who have difficulty in swallowing tablets or are experiencing severe pain. Rising cases of chronic diseases such as cancer, where pain management is crucial, can boost the demand for paracetamol IV solutions. Furthermore, rapid approval of new formulations and growing focus on pain management can present lucrative opportunities for global paracetamol IV market players over the forecast period.

Market Dynamics

Global paracetamol IV market growth is primarily driven by rising geriatric population worldwide who are more susceptible to chronic illnesses and injuries requiring pain management. According to the data published by the WHO, on October 1, 2024, the number of people aged 65 years or older is projected to increase from an estimated 524 million in 2010 to nearly 1.5 billion in 2050. Growing incidence of painful conditions like osteoporosis and arthritis in the elderly population boosts the need for potent intravenous painkillers. However, market growth can be hampered by certain challenges such as availability of alternative drugs and risk of adverse effects associated with prolonged usage of paracetamol IV. Ongoing medical advances in cancer research leads to the discovery of more effective therapies. This can boost demand for intravenous analgesics like paracetamol for managing chemotherapy-induced pain. Moreover, increasing focus of pharmaceutical companies on developing novel drug formulations can open new avenues for the paracetamol IV market.

Key features of the study

This report provides in-depth analysis of the global paracetamol IV market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global paracetamol IV market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Johnson & Johnson, Fresenius Kabi AG, Baxter International Inc., Pfizer Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Amgen Inc., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Mylan N.V., Eton Pharmaceuticals, Inc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global paracetamol IV market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paracetamol IV market

Market Segmentation

Type Insights (Revenue, USD Mn, 2019 - 2031)
- Single Dose
- Multi-Dose
Application Insights (Revenue, USD Mn, 2019 - 2031)
- Pain Management
- Fever Reduction
End User Insights (Revenue, USD Mn, 2019 - 2031)
- Hospitals
- Clinics
- Homecare Settings
- Others
Regional Insights (Revenue, USD Mn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson & Johnson
- Fresenius Kabi AG
- Baxter International Inc.
- Pfizer Inc.
- B. Braun Melsungen AG
- Hikma Pharmaceuticals PLC
- Amgen Inc.
- Sandoz (a Novartis division)
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Eton Pharmaceuticals, Inc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Apotex Inc.
- Mallinckrodt Pharmaceuticals

Product Code: CMI7565

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Paracetamol IV Market, By Type
- Global Paracetamol IV Market, By Application
- Global Paracetamol IV Market, By End User
- Global Paracetamol IV Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Paracetamol IV Market, By Type, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Single Dose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Multi-Dose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

5. Global Paracetamol IV Market, By Application, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Fever Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Paracetamol IV Market, By End User, 2019-2031, (USD Mn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Paracetamol IV Market, By Region, 2019 - 2031, (USD Mn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2020- 2031, (USD Mn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By End User, 2019 - 2031, (USD Mn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Mn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Baxter International Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
B. Braun Melsungen AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eton Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mallinckrodt Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

9. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. References and Research Methodology

References
Research Methodology
About us